Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 14 points (-0.1%) at 16,929 as of Tuesday, June 10, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 966 issues advancing vs. 1,989 declining with 165 unchanged. The Health Care sector currently is unchanged today versus the S&P 500, which is down 0.2%. Top gainers within the sector include Illumina ( ILMN), up 1.4%, Bristol-Myers Squibb Company ( BMY), up 0.7%, Teva Pharmaceutical Industries ( TEVA), up 0.6% and Gilead ( GILD), up 0.6%. On the negative front, top decliners within the sector include CR Bard ( BCR), down 3.9%, Jazz Pharmaceuticals ( JAZZ), down 3.6%, Actavis ( ACT), down 1.7%, Biogen Idec ( BIIB), down 1.6% and Regeneron Pharmaceuticals ( REGN), down 1.6%. TheStreet would like to highlight 3 stocks pushing the sector higher today: 3. Novo Nordisk A/S ( NVO) is one of the companies pushing the Health Care sector higher today. As of noon trading, Novo Nordisk A/S is up $1.09 (2.5%) to $44.29 on average volume. Thus far, 438,130 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $43.93-$44.50 after having opened the day at $43.94 as compared to the previous trading day's close of $43.20. Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $119.7 billion and is part of the drugs industry. Shares are up 16.9% year-to-date as of the close of trading on Monday. Currently there are 2 analysts who rate Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 1 rates it a hold. TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.